Evidence map›Paper›PMID 42747864›Full record

ArticleEuropean stroke journal2026

Efficacy and safety of minocycline in the treatment of intracerebral haemorrhage: study design and protocol for a multicentre, randomised, open-label, blinded endpoint clinical trial.

Yang Qu, Zhen-Ni Guo, Shuang Qi, Reziya Abuduxukuer, Peng Zhang, Huimin Li, Xin-Ni Lv, Zeng-Xin Xu, Yi Yang, ENHANCE Protocol Steering Group

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in European stroke journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yang QuStroke Center, Department of Neurology, the First Hospital of Jilin University, Changchun, China.
Zhen-Ni GuoStroke Center, Department of Neurology, the First Hospital of Jilin University, Changchun, China.
Shuang QiStroke Center, Department of Neurology, the First Hospital of Jilin University, Changchun, China.
Reziya AbuduxukuerStroke Center, Department of Neurology, the First Hospital of Jilin University, Changchun, China.
Peng ZhangStroke Center, Department of Neurology, the First Hospital of Jilin University, Changchun, China.
Huimin LiStroke Center, Department of Neurology, the First Hospital of Jilin University, Changchun, China.
Xin-Ni LvStroke Center, Department of Neurology, the First Hospital of Jilin University, Changchun, China.
Zeng-Xin XuStroke Center, Department of Neurology, the First Hospital of Jilin University, Changchun, China.
Yi YangStroke Center, Department of Neurology, the First Hospital of Jilin University, Changchun, China.ORCID 0000-0002-9729-8522
ENHANCE Protocol Steering Group

Funding

Science and Technology Department of Jilin Province 20250601002RC
6 · The paper itself

Abstract

backgroundAlthough minocycline is a multi-target neuroprotective drug, its potential benefit in patients with ICH remains unclear. This study primarily aims to assess the efficacy and safety of minocycline for the treatment of ICH. STUDY

designEfficacy and Safety of Minocycline in the Treatment of ICH (ENHANCE) is an ongoing prospective, multicentre, randomised, open-label, blinded-endpoint clinical trial. A total of 1248 patients with ICH within 24 h of onset will be randomly assigned to the minocycline or control group at a ratio of 1:1. The minocycline group will receive an initial dose of 200 mg minocycline hydrochloride capsules in addition to the guideline-based treatment, followed by 100 mg orally every 12 h for 7 days, resulting in a total of 14 administrations. The control group will receive only the guideline-based treatment. STUDY ENDPOINTS: The primary efficacy outcome measure will be the proportion of patients with good functional outcomes (mRS score, 0-2) at 180 days. Safety outcome measures will include all adverse events and severe adverse events occurring during the study period. SUMMARY: The ENHANCE trial is designed to evaluate the effectiveness and safety of minocycline in the treatment of ICH.

trial registrationChinese Clinical Trials Registry identifier: ChiCTR2500114607.

Indexed as

Anti-Bacterial AgentsCerebral HemorrhageMinocyclineNeuroprotective AgentsAdultAgedFemaleHumansMaleMiddle AgedMulticenter Studies as TopicProspective StudiesRandomized Controlled Trials as TopicResearch DesignTreatment OutcomeAnti-Bacterial AgentsMinocyclineNeuroprotective Agentsclinical trialintracerebral haemorrhageminocyclineprotocol

Identifiers

PMID42747864
PMCPMC13580077

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.